clinical trial · NCT03250377
A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization
UCB Biopharma SRL·phase3·completed·n = 207
Partial Seizures With or Without Secondary GeneralizationEpilepsyBrivaracetam
brief summary
The purpose of the study is to evaluate the long-term safety and tolerability of Brivaracetam (BRV) in focal epilepsy subjects with partial seizures and to evaluate the maintenance of efficacy of BRV over time.
started
Aug 5, 2017
primary completion
Dec 24, 2024
completion
Dec 24, 2024
last updated
Jul 29, 2025
official title
An Open-Label, Multicenter, Follow-up Study to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol